Lined up for the FDA in the coming weeks are a cell-based gene therapy for a rare skin disease and two product expansions for ...

After the gutting of the Department of Health and Human Services, fears mount about the future direction of the FDA—with ...

AI is enabling the development of a next generation of drugs that can more precisely target cancer cells while sparing ...

As the biopharma industry grapples with the uncertain macro environment brought on by the new administration, CEOs, ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Experts express concern that last week's unprecedented FDA layoffs will trigger a little-known mechanism that could result in ...

Novartis plans to build seven new facilities in the U.S., touting the creation of up to 1,000 new jobs at the company. The ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Biotech companies are already seeing regulatory delays and plenty of uncertainty after around 3,500 FDA employees were cut by ...

Analysts at William Blair expect drug developers will continue to perform “at least some animal testing” on their ...

Health and Human Services employees aren’t the only ones out of work. Thousands of private-sector biopharma professionals ...

The number of employees laid off dropped year over year during the first quarter. BioSpace recaps the five largest layoffs, ...